2005～2009年我院口服心脑血管类中成药应用分析  

Utilization Review of Oral Chinese Patent Drugs for Cardio-cerebral Vascular Diseases Used in Our Hospital from 2005 to 2009

作　　者：张乐平[1] 沈健[1] 

机构地区：[1]江苏省中医院药剂科,南京市210029

出　　处：《中国医院用药评价与分析》2010年第5期416-418,共3页Evaluation and Analysis of Drug-use in Hospitals of China

摘　　要：目的:分析我院口服心脑血管类中成药的应用情况及趋势。方法:对2005～2009年我院口服心脑血管类中成药的品种、销售金额、用药频度及限定日费用进行分析。结果:5年中我院口服心脑血管类中成药的销售金额和用药频度逐年增加,尤以活血通脉剂增长最快,单品种以银杏叶片稳居前列,血塞通软胶囊为增长最快的品种。结论:中成药在防治心脑血管疾病方面前景广阔,制药企业应抓住国家对中医药的扶持力度不断加大的契机,研发简、便、廉、验的中成药。OBJECTIVE： To analyze the status quo and the tendency of the utilization of oral Chinese patent drugs for cardio-cerebral vascular diseases in our hospital. METHODS： The drug varieties,consumption sum,DDDs and DDC of the oral Chinese patent drugs for cardio-cerebral vascular diseases used during 2005 ～ 2009 in our hospital were analyzed. RESULTS： In terms of consumption sum and DDDs,the oral Chinese patent drugs for cardio-cerebral vascular diseases used in our hospital increased year by year overe the five years,much as in those categories for activating and promoting blood circulation. Ginkgo Biloba Leaves Extract Tablets occupied the front place in both consumption sums and DDDs as a single variety,and the consumption of Sanqi Panax Notoginseng soft capsules increased most rapidly. CONCLUSION： The prospect of the Chinese patent drugs for preventing and treating cardio-cerebral vascular diseases is promising. In view of the increasing efforts put by China to support the traditional Chinese medicine industry,Chinese drug manufacturers should seize the opportunity to spare no effort to develop simple, convinent,cheap and effective Chinese patent drugs.

关 键 词：心脑血管病 中成药 销售金额 用药频度 限定日费用 

分 类 号：R972[医药卫生—药品]